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Objective. The aim of the study was to estimate the impact of whole body cryotherapy (WBC) on oxidative stress when performed in
a closed cryochamber on patients with ankylosing spondylitis (AS). Material and methods. The effect of ten WBC procedures
lasting 3 minutes a day with a subsequent 60-minute session kinesiotherapy on oxidative stress in male AS patients (WBC
group n = 16) was investigated. To assess the disease activity, the Bath Ankylosing Spondylitis Diseases Activity Index
(BASDAI) and Bath Ankylosing Spondylitis Functional Index (BASFI) were calculated. The WBC group was compared to the
kinesiotherapy only (KT; n = 16) group. The routine parameters of oxidative stress (antioxidant enzymatic and nonenzymatic
antioxidant status, lipid peroxidation products, total oxidative status (TOS), and oxidative stress index (OSI)) were estimated
one day before the beginning and one day after the completion of the research program. Results. After the completion of the
treatment in the WBC group, a significant decrease of oxidative stress markers (TOS and OSI) and a significant increase of total
antioxidant status were observed. The erythrocyte activity of glutathione peroxidase, glutathione reductase decreased
significantly in both groups, but the differences of activity of that enzymes prior to post treatment values (Δ) in the KT group
were significantly higher as compared to the WBC group. The activity of erythrocyte catalase and plasma ZnCu isoenzyme of
superoxide dismutase showed a decreased tendency; erythrocyte total superoxide dismutase activity showed an increased
tendency in the WBC group after the completion of the treatment. The BASDAI and BASFI decreased significantly in both
groups, but the differences of value indexes prior to post treatment (Δ) were significantly higher in the WBC than KT group.
Conclusion. WBC performed in a closed cryochamber decreases oxidative stress and improves BASDAI and BASFI indexes in
male patients during the active phase of ankylosing spondylitis.
1. Introduction
Ankylosing spondylitis (AS) is a chronic, usually progressive
inflammatory rheumatic disease with severe complications
that include sacroiliitis, spondylodesis, peripheral arthritis,
and a range of extra-articular manifestations, ultimately lead-
ing to impacts upon mobility and societal functioning [1].
The pathogenesis of AS is still unknown, but lately it has been
postulated that oxidative stress might be involved in the dis-
ease [2–6]. Oxidative stress can induce acute or chronic
inflammation through the activation of multiple pathways.
When oxidative stress appears as a primary disorder, inflam-
mation develops as a secondary disorder and further
enhances oxidative stress [7].
In addition to pharmacological treatment, physiotherapy
plays an important role in the treatment of AS patients. They
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are commonly used to maintain spinal mobility, decrease
spinal deformity, and reduce pain as well as improve patient’s
functioning and quality of life [8, 9].
More and more frequently, whole-body cryotherapy
(WBC), as a method of physical medicine, is used in the treat-
ment of rheumatic and inflammatory diseases and muscle
spasticity [10]. DuringWBC treatment, the subject is exposed
to extreme cold temperatures (below −100°C) for a short
period of time (maximum up to 3 minutes) [11, 12]. The
action of cryogenic temperatures causes several favorable
physiological reactions such as an analgesic, anti-inflamma-
tory, and a circulatory effect [12–15]. Cryogenic temperatures
applied to the whole body, apart from the aforementioned
effects, also have significant influence on the psyche, the
immune, and endocrine systems [15–18].
However, little is still known about the mechanisms of
WBC treatment in AS patients. So far, it has been showed
that WBC procedures with subsequent kinesiotherapy may
help to decrease pain and inflammatory parameters,
improve BASDAI (Bath Ankylosing Spondylitis Diseases
Activity Index) and BASFI (Bath Ankylosing Spondylitis
Functional Index) indexes, and some spinal mobility param-
eters [19–21]. It has been also proven that in AS patients,
WBC treatment performed in a cryochamber with cold
retention may decrease oxidative stress and lipid profile
parameters [22].
However, the effect of WBC treatment may depend on
the type of cryochamber in which procedures are performed
[21, 22]. The most popular cryochambers are chambers with
cold retention and closed ones (called Wroclawski type or
two-step cryochamber).
In the cryochamber with cold retention, in order to make
use of the “cold deposit” phenomenon, the cryogenic cham-
ber is placed about 2.5m under floor level. It is cooled by
synthetic liquid air. The subjects enter the therapy chamber
by stairs which constitute a mild adaptive area. An open ante-
chamber (vestibule) is located at the base of the stairs. The
vestibule and the proper chamber are separated by double
swing doors [23, 24].
The closed Wroclawski-type cryochamber is placed at
floor level. It is usually cooled by liquid nitrogen. The vesti-
bule and the proper chamber are located on the same level
and separated by a lockable door [24].
But until now, there are no papers in available literature
on the impact of WBC treatment performed in a closed cryo-
chamber (Wroclawski type) on oxidative stress in AS patients.
In light of the above findings, and taking account that
WBC treatment may be performed in different types of
cryochambers, the primary aim of the study was to assess
the influence of WBC performed in a closed cryochamber
(Wroclawski type) on oxidative stress in AS patients during
the active phase.
2. Materials and Methods
2.1. Subjects. The research was conducted with the consent of
the Bioethical Committee of the Medical University of Silesia
in Katowice (permission number NN-6501-93/I/07), Poland.
All examined subjects provided written informed consent.
All investigations were conducted according to the principles
expressed in the Declaration of Helsinki (1964).
The research involved a group of 32 nonsmoking male
patients with ankylosing spondylitis who were divided ran-
domly by a physician into two groups with an allocation
ratio 1 : 1. The first group consisted of 16 AS patients
exposed to whole-body cryotherapy procedures with subse-
quent kinesiotherapy (WBC group, mean age 46.63 ± 1.5
years). The second group consisted of 16 AS patients exposed
only to kinesiotherapy procedures (KT group, mean age
45.94 ± 1.24 years). There was no significant difference in
the mean age, BMI, BASDAI, BASFI, and treatment between
these groups.
Male patients who were successfully enrolled in the
research had a definite diagnosis of AS, did not suffer from
any other diseases, had no associated pathologies, and had
no treatment with disease-modifying antirheumatic drugs
(DMARDs), biologic agents, or steroids. The AS patients
were treated with doses of nonsteroidal anti-inflammatory
drugs (NSAIDs), which were not altered within one month
before the beginning of the study and during it. All the
patients included in the trial fulfilled the modified New York
Criteria for definite diagnosis of AS, which serves as the basis
for the ASAS/EULAR recommendations [25]. The final
selection for the study included only HLA B27 positive
patients, who exhibited II and III radiographic grades of
sacroiliac joint disease and attended a consulting unit in a
health resort in the period of subsidence of acute clinical
symptoms, in order to qualify for physiotherapy treatment.
The demographic characteristics of the subjects is shown in
Table 1.
Before the research, each patient was examined by a
physician to exclude any coexisting diseases as well as any
contraindications for WBC procedures. Prior to the research,
a resting electrocardiogram was performed in all the patients,
and before each session of WBC, the blood pressure was
measured for each patient [24].
The patients from both groups were asked to abstain
from alcohol, drugs, and any immunomodulators, immu-
nostimulators, hormones, vitamins, minerals, or other sub-
stances with antioxidant properties for 4 weeks before the
study. All the patients were also asked to refrain from the
consumption of caffeine 12 hours prior to laboratory analy-
ses. The diet of the patients was not modified.
2.2. Scheme of Whole-Body Cryotherapy and Kinesiotherapy
Procedures. Depending on the group, the AS patients were
exposed either to a cycle of WBC procedures lasting 3
minutes a day with a subsequent 60-minute session of
kinesiotherapy or 60-minute session of kinesiotherapy only
for 10 consecutive days excluding the weekend at the same
time in the morning.
The WBC procedures were performed in a cryochamber
Wroclawski type (closed cryochamber) cooled by liquid
nitrogen (produced by Creator, Poland), which consisted of
separated two compartments: the antechamber (vestibule)
and the proper chamber. The temperature in the antechamber
was−60°C,whereas in the proper chamber, it reached−120°C.
The subjects entered the chamber in groups of four. Each
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entry to the cryochamber was preceded by a 30-second adap-
tation period in the vestibule at −60°C. After adaptation, the
subjects stepped into the proper chamber, where they were
exposed to cryogenic temperatures for 3 minutes. During
the WBC procedure, all the patients were dressed in swim-
suits, they wore cotton socks and gloves and wooden shoes,
and their mouths and noses were protected by dust masks
and their ears by ear-protectors. No jewelry, glasses, and
contact lenses were allowed. Each subject was informed
about the rules: the need for slow, shallow breathing (short
nasal inhalation and longer oral exhalation), and the way
to move about (slow walking in circles, one after the other).
During the WBC procedure, they were also not allowed to
touch each other.
Immediately after leaving the cryogenic chamber, the AS
patients underwent kinesiotherapy lasting for one hour. The
program of kinesiotherapy was the same for all the patients in
both groups. Kinesiotherapy procedures included range-of-
motion exercises of the spine and major joints (including
the hip, knee, ankle, shoulder, elbow, and wrist). Chest
expansion and breathing exercises were also included. Apart
from range-of-motion exercise, the AS patients received
strengthening exercises of the muscles of the major body
parts (spine, arms, and thighs) as well as aerobic exercise
(including cycling and fast walking). All the exercises were
carried out under the supervision of physiotherapists [22].
All the patients completed the research program and no
complications or side effects related to the WBC procedures
were observed.
2.3. Blood Sample Collection. Blood samples of all the subjects
were collected in the morning before the first meal one day
before the beginning and one day after the completion of the
research program. Samples of whole blood (5ml) were drawn
from the basilic vein and then collected into tubes containing
ethylenediaminetetraacetic acid (Sarstedt, S-Monovette with
1.6mg/ml EDTA-K3) and into tubes with a clot activator
(Sarstedt, S-Monovette). The blood samples were centrifuged
(10min., 900g 4°C) and then the plasma and serum
were immediately separated and stored at the temperature
of −75°C, until biochemical analyses could be performed.
The red blood cells retained from the removal of EDTA
plasma were rinsed with isotonic salt solution, and then 10%
of the hemolysates were prepared for further analyses. The
hemoglobin concentration in the hemolysates was deter-
mined by the standard cyanmethemoglobin method. The
inter- and intra-assay coefficients of variations (CV) were
1.1% and 2.4%, respectively.
2.4. Biochemical Analysis
2.4.1. Oxidative Stress Analysis
(1) Determination of Activity of Antioxidant Enzymes. The
plasma and erythrocytes superoxide dismutase (SOD-
E.C.1.15.1.1) activity was assayed by the Oyanagui method
[26]. Enzymatic activity was expressed in nitrite unit (NU)
in each mg of hemoglobin (Hb) or ml of blood plasma.
One nitrite unit (1 NU) means a 50% inhibition of nitrite
ion production by SOD in this method. SOD isoenzymes
(SOD-Mn and SOD-ZnCu) were measured using potassium
cyanide as the inhibitor of the SOD-ZnCu isoenzyme. The
inter- and intra-assay coefficients of variations (CV) were
2.8% and 5.4%, respectively.
The catalase (CAT-E.C.1.11.1.6.) activity in erythrocytes
was measured by the Aebi [27] kinetic method and expressed
in [IU/mgHb]. The inter- and intra-assay coefficients of
variations (CV) were 2.6% and 6.1%, respectively.
The activity of erythrocyte glutathione peroxidase (GPx-
E.C.1.11.1.9.) was assayed by Paglia and Valentine’s kinetic
method [28], with t-butyl peroxide as a substrate and
expressed as micromoles of NADPH oxidized per minute
and normalized to one gram of hemoglobin [IU/gHb]. The
inter- and intra-assay coefficients of variations (CV) were
3.4% and 7.5%, respectively.
The glutathione reductase in erythrocytes (GR-
E.C.1.6.4.2) activity was assayed by Richterich’s kinetic
method [29], expressed as micromoles of NADPH utilized
per minute and normalized to one gram of hemoglobin
[IU/g Hb]. The inter- and intra-assay coefficients of varia-
tions (CV) were 2.1% and 5.8%, respectively.
Table 1: Demographic characteristics of the research subjects.
Characteristic
WBC group
(n = 16)
Kinesiotherapy group
(n = 16) p value
Age, years, mean (SD) 46.63 ± 1.5 45.94 ± 1.24 0.114
Sex M/F 16/0 16/0 —
BMI, kg/m2, mean (SD) 24.35 ± 4.4 23.76 ± 6.8 0.968
BASDAI 5.34 ± 1.72 5.28 ± 1.71 0.880
BASFI 5.17 ± 2.28 5.01 ± 2.06 0.940
Smoking (yes/no) 0/16 0/16 —
Medication
NSAID (yes/no) 16/0 16/0 —
DMARD (yes/no) 0/16 0/16 —
Biological agents (yes/no) 0/16 0/16 —
SD: standard deviation; BMI: body mass index; BASDAI: the Bath Ankylosing Spondylitis Diseases Activity Index; BASFI: the Bath Ankylosing Spondylitis
Functional Index; NSAID: nonsteroidal anti-inflammatory drug; DMARD: disease-modifying antirheumatic drug.
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(2) Determination of Nonenzymatic Antioxidant Status. The
total antioxidant capacity of plasma was measured as the fer-
ric reducing ability of plasma (FRAP) according to Benzie
and Strain [30] and calibrated using Trolox and expressed
in [μmol/l]. The inter- and intra-assay coefficients of varia-
tions (CV) were 1.1% and 3.8%, respectively.
The serum concentration of protein sulfhydryl (PSH)
was measured by Koster et al.’s method [31] using dithioni-
trobenzoic acid (DTNB) and expressed in [μmol/l]. The
inter- and intra-assay coefficients of variations (CV) were
2.6% and 5.4%, respectively.
The serum concentration of uric acid (UA) was assayed
by a uricase-peroxidase method [32] on the Cobas Integra
400 plus analyzer and expressed as [mg/dl]. The inter- and
intra-assay coefficients of variations (CV) were 1.4% and
4.4%, respectively.
(3) Determination of Lipid Peroxidation Products, Total
Oxidatative Status, and Oxidative Stress Index. The intensity
of lipid peroxidation in the plasma and the erythrocytes was
measured spectrofluorimetrically as thiobarbituric acid-
reactive substances (TBARS) according to Ohkawa et al.
[33]. The TBARS concentrations were expressed as malon-
dialdehyde (MDA) equivalents in [μmol/l] in plasma or
[nmol/gHb] in erythrocytes. The inter- and intra-assay coef-
ficients of variations (CV) were 2.1% and 8.3%, respectively.
The serum total oxidant status (TOS) was determined
with the method described by Erel [34] and expressed in
[μmol/l]. The inter- and intra-assay coefficients of variations
(CV) were 2.2% and 6.4%, respectively.
The oxidative stress index (OSI), an indicator of the
degree of oxidative stress, was expressed as the ratio of total
oxidant status (TOS) to total antioxidant capacity (FRAP)
in arbitrary units [35].
2.5. Assessment of Activity of Ankylosing Spondylitis. The
activity of ankylosing spondylitis was measured by the Bath
Ankylosing Spondylitis Diseases Activity Index (BAS-
DAI) and the Bath Ankylosing Spondylitis Functional
Index (BASFI).
The BASDAI has six questions related to fatigue, back
pain, peripheral pain, peripheral swelling, local tenderness,
and morning stiffness (degree and length). Other than the
issues relating to morning stiffness, all questions were scored
from 0 (none) to 10 (very severe) using a visual analogue
scale (VAS). The sum was calculated as the mean of two
morning stiffness issues and the four remaining issues [36].
The BASFI is the mean score of ten questions addressing
functional limitations and the level of physical activity at
home and work, assessed on VAS scales (0 = easy,
10= impossible) [37].
2.6. Statistical Analysis. For statistical analysis, the statistical
package of Statistica 10 Pl software was used. For each
parameter, the indicators of the descriptive statistics were
determined (mean value and standard deviation SD). The
normality of the data distribution was checked using the
Shapiro–Wilk test, while the homogeneity of the variance
was checked by applying the Levene’s test. In order to
compare the differences between the groups, an independent
sample Student t-test was used or alternatively the
Mann–Whitney U test. In the case of dependent samples,
the Student t-test was used or alternatively the Wilcoxon
test. Differences at the significance level of p < 0 05 were
considered as statistically significant.
3. Results
3.1. Antioxidants Enzymes. AS patients in the WBC group
had, after the completion of treatment, a statistically signif-
icant decrease in the erythrocyte activity of GPx (20.6± 5.07
and 18.3± 4.15 [IU/gHb]—before and after therapy,
respectively, p = 0 002) and GR (1.21± 0.29 and 0.93± 0.37
[IU/gHb] [IU/gHb]—before and after therapy, respectively,
p = 0 007). The erythrocyte activity of CAT (423.0± 61.6
and 380.0± 102.0 [IU/mgHb]—before and after therapy,
respectively, p = 0 079) and plasma SOD-CuZn (7.05± 1.92
and 5.76± 2.36 [NU/ml]—before and after therapy,
respectively, p = 0 063) showed a decreased tendency. The
erythrocyte activity of total SOD (104.0 ± 15.0 and 112.0±
11.2 [NU/mgHb]—before and after therapy, respectively,
p = 0 056) showed an increased tendency.
However, the activity of plasma total SOD (12.4± 1.89
and 11.5± 3.19 [NU/ml]—before and after therapy, respec-
tively, p = 0 501) and SOD-Mn (5.31± 1.03 and 6.32± 2.16
[NU/ml]—before and after therapy, respectively, p = 0 098)
did not change significantly in the WBC group after treat-
ment. Similarly, as in the WBC group, the activity of plasma
total SOD (12.3 ± 1.85 and 11.7 ± 2.49 [NU/ml]—before
and after therapy, respectively, p = 0 301) and SOD-Mn
(4.56 ± 1.86 and 5.02 ± 1.64 [NU/ml]—before and after
therapy, respectively, p = 0 642) did not change significantly
in the KT group after treatment. In the KT group, the
erythrocyte activity of total SOD (128.0 ± 11.2 and
111.0 ± 15.6 [NU/mgHb]—before and after therapy,
respectively, p = 0 001), GPx (29.9 ± 2.84 and 20.4 ± 5.05
[IU/gHb]—before and after therapy, respectively, p = 0 001)
and GR (2.07 ± 0.52 and 1.65 ± 0.59 [IU/gHb]—before and
after therapy, respectively, p = 0 002), similar to the WBC
group of patients, decreased significantly after treatment.
Additionally, the differences of activity of erythrocyte total
SOD (−17.1 ± 11.8 [NU/mgHb] in the KT group versus
7.77± 17.2 [NU/mgHb] in the WBC group, p < 0 001) and
GPx (−9.49 ± 6.74 [IU/gHb] in the KT group versus −2.27±
1.98 [IU/gHb] in the WBC group, p = 0 001) prior to post-
treatment values (Δ) in theKT groupwere significantly higher
as compared to the WBC group. In the KT group, the activity
of erythrocyte CAT (425.0 ± 53.6 and 412.0 ± 58.6
[IU/mgHb]—before and after therapy, respectively, p = 0 352)
and plasma SOD-CuZn (7.80 ± 2.21 and 7.05 ± 3.09
[NU/ml]—before and after therapy, respectively, p = 0 326)
did not change significantly after treatment in comparison
to the WBC group (Table 2).
3.2. Nonenzymatic Antioxidant Status. In the WBC group
FRAP values (514.1± 63.2 and 587.9± 50.9 [μmol/l]—before
and after therapy, respectively, p = 0 001) increased signifi-
cantly after treatment. The UA level showed an increased
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tendency in WBC group of patients (4.44 ± 1.43 and
4.75± 1.08 [mg/dl]—before and after therapy, respectively,
p = 0 066). After completion of the treatment FRAP values
were significantly higher in the WBC group (587.9± 50.9
[μmol/l] when compared to the KT group (499.3± 74.6
[μmol/l]) (p = 0 001). The level of PSH (627.6± 248.0 and
616.5± 279.1 [μmol/l]—before and after therapy, respec-
tively, p = 0 918) in the WBC group of patients did not
change significantly after treatment. In turn, FRP values
(550.0± 91.3 and 499.3± 74.6 [μmol/l]—before and after
therapy, respectively, p = 0 001) and PSH concentration
(393.2± 90.0 and 364.7± 28.4 [μmol/l]—before and after
therapy, respectively, p = 0 017) decreased significantly, in
the KT group, but the level of UA (4.34± 1.15 and
4.61 ± 1.25 [mg/dl]—before and after therapy, respectively,
p = 0 196) did not change significantly after treatment
(Table 3).
3.3. Lipid Peroxidation Products, Total Oxidative Status, and
Oxidative Stress Index. AS patients in the WBC group
had, after the completion of the treatment, a statistically
significant decrease in serum TOS (30.49± 13.35 and
14.56± 9.01[μmol/l]—before and after therapy, respectively,
p = 0 003) and value of OSI index (64.19± 65.93 and 10.20±
3.79—before and after therapy, respectively, p = 0 001) in
comparison to initial values. The differences of these
parameters prior to posttreatment values in the WBC group
were significantly higher in comparison to the KT group
(ΔTOS −15.93± 17.04 [μmol/l] in the WBC group versus
0.46± 9.11[μmol/l] in the KT group, p = 0 003; Δ OSI
−53.99± 66.83 in WBC group versus 4.78± 13.88 in the
KT group, p = 0 003). The levels of MDA in plasma
(2.66± 0.73 and 2.48± 0.57 [μmol/l]—before and after
therapy, respectively, p = 0 215) and in erythrocyte (0.16±
0.01 and 0.15± 0.02 [nmol/gHb]—before and after therapy,
respectively, p = 0 098) did not change significantly in the
WBC group. In the KT group, no significant changes in
the levels of plasma MDA (2.32± 0.60 and 2.41± 0.83
[μmol/l]—before and after therapy, respectively, p = 0 959)
and erythrocyte MDA (0.18± 0.02 and 0.18± 0.04 [nmol/
gHb]—before and after therapy, p = 0 642) as well as serum
TOS (23.94± 11.60 and 24.41± 6.24 [μmol/l]—before and
after therapy, respectively, p = 0 605) and OSI index
(18.87± 11.30 and 23.65± 15.68—before and after therapy,
respectively, p = 0 301) were observed after the completion
of treatment, in comparison to the initial values before the
beginning of the kinesiotherapy cycle (Table 4).
Table 2: Activities of antioxidant enzymes (mean value± standard
deviation SD) in AS patients before and after the completion of a
cycle of ten whole-body cryotherapy procedures with subsequent
kinesiotherapy (WBC group) or a cycle of ten kinesiotherapy
procedures only (KT group), with statistical analyses. (p): plasma;
(e): erythrocyte lysates; Δ: difference prior to post treatment.
Parameters WBC group KT group p
Total SOD (p)
[NU/ml]
Before 12.4± 1.89 12.3± 1.85 0.927
After 11.5± 3.19 11.7± 2.49 0.884
P∗ 0.501 0.301
Δ −0.81± 3.08 −0.60± 2.65 0.837
SOD-Mn (p)
[NU/ml]
Before 5.31± 1.03 4.56± 1.86 0.170
After 6.32± 2.16 5.02± 1.64 0.066
P∗ 0.098 0.642
Δ 1.01± 2.15 0.46± 2.46 0.509
SOD-CuZn (p)
[NU/ml]
Before 7.05± 1.92 7.80± 2.21 0.310
After 5.76± 2.36 7.05± 3.09 0.194
P∗ 0.063 0.326
Δ −1.29± 2.46 −0.75± 2.72 0.166
Total SOD (e)
[NU/mgHb]
Before 104.0 ± 15.0 128.0± 11.2 <0.001
After 112.0 ± 11.2 111.0± 15.6 0.759
P∗ 0.056 0.001
Δ 7.77± 17.2 −17.1± 11.8 <0.001
CAT (e)
[IU/mgHb]
Before 423.0± 61.6 425.0± 53.6 0.914
After 380.0± 102.0 412.0± 58.6 0.294
P∗ 0.079 0.352
Δ −42.3± 109.0 −13.0± 54.0 0.347
GPx (e)
[IU/gHb]
Before 20.6± 5.07 29.9± 2.84 <0.001
After 18.3± 4.15 20.4± 5.05 0.207
P∗ 0.002 0.001
Δ −2.27± 1.98 −9.49± 6.74 0.001
GR (e)
[IU/gHb]
Before 1.21± 0.29 2.07± 0.52 <0.001
After 0.93± 0.37 1.65± 0.59 <0.001
P∗ 0.007 0.002
Δ −0.28± 0.34 −0.42± 0.41 0.275
P: statistical significance of differences between both groups of patients;
P∗: statistical significance of differences between values before and after
treatment in particular groups of subjects.
Table 3: Levels of nonenzymatic antioxidants (mean value±
standard deviation SD) in AS patients before and after the
completion of a cycle of ten whole-body cryotherapy procedures
with subsequent kinesiotherapy (WBC group) or a cycle of ten
kinesiotherapy procedures only (KT group), with statistical
analyses. (p): plasma; (s): serum;Δ: difference prior to post treatment.
Parameters WBC group KT group p
FRAP
[μmol/l
Before 514.1± 63.2 550.0± 91.3 0.206
After 587.9± 50.9 499.3± 74.6 0.001
P∗ 0.001 0.001
Δ 73.9± 55.0 −50.8± 39.4 <0.001
PSH (s)
[μmol/l]
Before 627.6± 248.0 393.2± 90.0 0.772
After 616.5± 279.1 364.7± 28.4 0.239
P∗ 0.918 0.017
Δ −11.1± 281.7 −28.5± 92.6 0.605
UA (s)
[mg/dl]
Before 4.44± 1.43 4.34± 1.15 0.838
After 4.75± 1.08 4.61± 1.25 0.738
P∗ 0.066 0.196
Δ 0.31± 1.02 0.27± 0.70 0.885
P: statistical significance of differences between both groups of patients;
P∗: statistical significance of differences between values before and after
treatment in particular groups of patients.
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3.4. BASDAI and BASFI Indexes. The BASDAI (5.34 ± 1.72
and 3.19± 0.91 in the WBC group—before and after therapy,
respectively, p = 0 001; 5.28± 1.71 and 4.53± 1.62 in the KT
group—before and after therapy, respectively, p < 0 001)
and BASFI (5.17± 2.28 and 3.79± 2.21 in the WBC
group—before and after therapy, respectively, p < 0 001;
5.01± 2.06 and 4.35± 2.23 in the KT group—before and after
therapy, respectively, p < 0 001) indexes decreased signifi-
cantly in both groups, but in the WBC group, with subse-
quent kinesiotherapy after the completion of the treatment,
the decrease of these parameters was significantly higher in
comparison to the KT group (Δ BASDAI −2.16± 1.29 in the
WBC group versus −0.74± 0.38 in the KT group, p < 0 001;
Δ BASFI −1.38± 1.07 in the WBC group versus −0.66± 0.39
in the KT group, p = 0 007). The value of both BASDAI
and BASFI indexes was below 4 (inactive phase of AS
disease) only in the WBC group after the completion of
treatment (Table 5).
4. Discussion
After the completion of the treatment, a significant decrease
in markers of oxidative stress was achieved in the WBC
group of AS patients who underwent a ten-day long cycle
of WBC procedures with subsequent kinesiotherapy. In that
group of patients, a significant decrease in levels of TOS
and OSI values as well as in activity of erythrocyte GPx and
GR was observed. A decreased tendency was also noticed in
the activity of plasma SOD-CuZn and erythrocyte CAT.
Contrary, an increased tendency was seen in the activity of
erythrocyte total SOD and the level of UA after the comple-
tion of treatment in the WBC group. The FRAP value was
increased significantly after the completion of treatment in
the WBC group. No significant changes were noted in the
activity of plasma total SOD and SOD-Mn, as well as levels
of PSH and both plasma and erythrocyte MDA after the
completion of treatment in the WBC group.
These findings are similar to our previous research, in
which a beneficial impact on oxidative stress from ten
WBC procedures performed in a cryochamber with cold
retention (temperature: −120°C, time: 3min, liquid air cool-
ant) both in healthy subjects and AS patients was observed
[22, 38]. It has been suggested by Mila-Kierzenkowska et al.
[23] that even a single application of cryotherapy prior to
exercise may have a beneficial impact on antioxidant system
of organism and alleviate the signs of exercise-induced oxida-
tive stress (a single session of WBC, temperature: −130°C,
time: 1-2min., cryochamber with cold retention, liquid
air coolant).
However, it has been shown by Lubkowska et al. [39]
that a single session of WBC (temperature: −130°C, time:
3 minutes, two-step cryochamber, liquid nitrogen coolant)
could induce disturbances in prooxidant-antioxidant bal-
ance, in the form of lowering TOS and a temporary
decrease in TAS, with a subsequent elevation of those param-
eters on the following day, resulting in an intensification of
oxidative stress.
In another study by the same team [39], healthy men
have been exposed to a single WBC session (temperature:
−130 °C, time 3minutes, two-step cryochamber, liquid nitro-
gen coolant) without subsequent kinesiotherapy. A signifi-
cant increase in GPx and GR activities, with a simultaneous
decrease in CAT and glutathione S-transferase activities,
was observed. A significant increase in the concentration
Table 4: Levels of lipid peroxidation parameters, total oxidative
status (TOS), and oxidative stress (OSI) index (mean value
± standard deviation SD) in AS patients before and after the
completion of a cycle of ten whole-body cryotherapy procedures
with subsequent kinesiotherapy (WBC group) or a cycle of ten
kinesiotherapy procedures only (KT group), with statistical
analyses. (p): plasma; (s): serum; (e): erythrocyte lysates; Δ:
difference prior to post treatment.
Parameters WBC group KT group p
MDA (p)
[μmol/l]
Before 2.66± 0.73 2.32± 0.60 0.157
After 2.48± 0.57 2.41± 0.83 0.783
P∗ 0.215 0.959
Δ −0.19± 0.72 0.09± 1.04 0.391
MDA (e)
[nmol/gHb]
Before 0.16± 0.01 0.18± 0.02 0.001
After 0.15± 0.02 0.18± 0.04 0.001
P∗ 0.098 0.642
Δ −0.01± 0.03 0.00± 0.04 0.155
TOS (s)
[μmol/l]
Before 30.49± 13.35 23.94± 11.60 0.149
After 14.56± 9.01 24.41± 6.24 0.001
P∗ 0.003 0.605
Δ −15.93± 17.04 0.46± 9.11 0.003
OSI (p/s)
[arbitrary unit]
Before 64.19± 65.93 18.87± 11.30 0.016
After 10.20± 3.79 23.65± 15.68 0.004
P∗ 0.001 0.301
Δ −53.99± 66.83 4.78± 13.88 0.003
P: statistical significance of differences between both groups of patients;
P∗: statistical significance of differences between values before and after
treatment in particular groups of patients.
Table 5: The value of BASDAI and BASFI indexes (mean value±
standard deviation SD) in AS patients before and after the
completion of a cycle of ten whole-body cryotherapy procedures
with subsequent kinesiotherapy (WBC group) or a cycle of ten
kinesiotherapy procedures only (KT group), with statistical
analyses. (p): plasma; (s): serum;Δ: difference prior to post treatment.
Parameters WBC group KT group p
BASDAI index
Before 5.34± 1.72 5.28± 1.71 0.880
After 3.19± 0.91 4.53± 1.62 0.030
P∗ 0.001 <0.001
Δ −2.16± 1.29 −0.74± 0.38 0.001
BASFI index
Before 5.17± 2.28 5.01± 2.06 0.940
After 3.79± 2.21 4.35± 2.23 0.406
P∗ <0.001 <0.001
Δ −1.38± 1.07 −0.66± 0.39 0.007
P: statistical significance of differences between both groups of patients;
P∗: statistical significance of differences between values before and after
treatment in particular groups of patients.
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of glutathione, uric acid, albumins, and extra-erythrocyte
hemoglobin was also observed in the serum of the subjects.
It was concluded by the authors that a single stimulation
with cryogenic temperatures results in oxidative stress in a
healthy body, but the level of this stress is not very high.
It has been suggested that repeated exposure to cryogenic
temperatures may cause adaptative changes in the form of an
increase in antioxidant status and antioxidant enzyme activ-
ity, resulting in the formation of a prooxidant-antioxidant
balance at a higher level (according to hormesis theory) [40].
A beneficial impact of WBC on prooxidant-antioxidant
balance has been observed in bothmale and female kayak ath-
letes when WBC procedures were included into the training
regime [40, 41]. The increase in total antioxidant status and
the level of UA as a result of a series of short-term whole-
body cryotherapy (10 WBC sessions, temperature: −130°C,
time: 3minutes, without subsequent kinesiotherapy) has been
also observed by Miller et al. [42] in healthy subjects. How-
ever, in other study [43], the authors have shown that the
activity of antioxidant enzymes in healthy men depends on
the number of WBC procedures (temperature: −130°C, time:
3 minutes). It was also suggested that WBC intensifies oxida-
tive stress and causes an accompanying decrease in antioxi-
dant enzyme activity after 10 sessions, with a subsequent
compensatory increase after the completion of a cycle of 20
sessions. In a different study [44], patients with seropositive
rheumatoid were observed by the authors to have only a
short-term increase in TRAP during the first treatment ses-
sion of WBC (the temperature− 110°C, three times daily for
7 consecutive days), and no significant oxidative stress or
adaptation were caused by the cold treatment.
In our research a significant decrease in BASDAI and
BASFI indexes in the WBC group after the completion of
treatment was observed. These results are similar to our pre-
vious research, in whichWBC procedures were performed in
a cryochamber with cold retention and two-step cryocham-
ber (Wroclawski type) [19, 22]. In both studies, after the
completion of a cycle of WBC procedures consisting of ten
3 minute long WBC procedures daily with subsequent kine-
siotherapy (temperature− 120°C, time 3min, 10 sessions with
a weekend break), a decreased of the BASDAI and BASFI
index below 4 was observed, which suggests that the AS
disease turned into an inactive phase after the completion
of treatment. Similar results in AS patients have also been
observed by Romanowski et al. [20] (8 daily WBC proce-
dures, the temperature −110°C, time 3min).
The differences in the results of various studies may be
related to the type of cryochamber being used and the coolant
medium, in addition to the time of exposure to cryogenic
temperatures. Further studies are necessary to estimate
whether the number of WBC procedures and type of cryo-
chamber may have an influence on prooxidant-antioxidant
balance in subjects who underwent WBC treatment. Compa-
rability of the results obtained by different research teams
could be improved through standardization of exposure
times and the number of treatments during each cycle. In
an attempt to optimise treatment, sexually dimorphism, body
fat percentage, and BMI differences should be also taken into
account [45, 46].
The present study has some limitations. Firstly, the study
did not provide long-term follow-up (at least 3 months), and
thus we are not sure how long the beneficial effect of WBC
with subsequent kinesiotherapy would be maintained after
the completion of a WBC cycle. Secondly, the cycle of
WBC with subsequent kinesiotherapy consisted of ten proce-
dures only. A greater number of procedures (e.g., 20–30)
could probably intensify the treatment effect. Thirdly,
the next studies should involve a larger number of AS
patients in different stages of the disease. Females should be
also included.
5. General Conclusion
Whole-body cryotherapy procedures performed in a closed
cryochamber (Wroclawski type) with subsequent kine-
siotherapy decrease oxidative stress as well as BASDAI and
BASFI indexes in AS patients during the active phase of
the disease.
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